GSK reported a better-than-expected top-line performance in Q3 – sales grew by 6% at CER to £8.1bn, on the back of excellent sales of the shingles vaccine, Shingrix, and a steady performance across the board. The US (+13%) was the biggest contributor, followed by the international markets (+4%), while Europe faced a decline of 2%. The lower end of the adjusted EPS guidance for the year was upgraded – from 7-10% to 8-10%, irrespective of the generic competition for Advair.
....21 Nov 2018
Another strong quarter without Advair generic
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Another strong quarter without Advair generic
GSK plc (GSK:LON) | 1,643 115 0.4% | Mkt Cap: 68,111m
- Published:
21 Nov 2018 -
Author:
Kamla Singh -
Pages:
3
GSK reported a better-than-expected top-line performance in Q3 – sales grew by 6% at CER to £8.1bn, on the back of excellent sales of the shingles vaccine, Shingrix, and a steady performance across the board. The US (+13%) was the biggest contributor, followed by the international markets (+4%), while Europe faced a decline of 2%. The lower end of the adjusted EPS guidance for the year was upgraded – from 7-10% to 8-10%, irrespective of the generic competition for Advair.
....